Is Teladoc Health a Hidden Bargain After 70% Stock Slide and Shifting Telehealth Trends?
- Wondering if Teladoc Health is a hidden bargain or just another falling star? Let’s dig into what the numbers and market sentiment are really telling us.
- After shedding 1.3% over the past week and only eking out a 0.4% gain over the last month, the stock is still down 13.6% year-to-date and has plunged an eye-popping 70.6% in the past three years.
- Recent headlines have focused on the shifting landscape for telehealth adoption, with policy changes and partnership expansions making waves. Industry buzz surrounding the staying power of digital healthcare is adding new fuel to debates about the company’s true potential.
- On the valuation front, Teladoc Health scores a 5 out of 6 on Simply Wall St's value checks, which you can see for yourself here. Traditional valuation tools tell part of the story, but it is worth taking a deeper look at what really moves the needle.
Find out why Teladoc Health's -7.1% return over the last year is lagging behind its peers.
Approach 1: Teladoc Health Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow (DCF) model estimates a company’s value by projecting its future cash flows and discounting them back to today using a required rate of return. This approach helps investors evaluate whether the current share price reflects the company’s long-term potential.
For Teladoc Health, the latest reported Free Cash Flow stands at $148.3 million. Analysts forecast steady growth over the coming years, with Free Cash Flow expected to reach $207.7 million by 2029. Although detailed analyst estimates only extend five years out, Simply Wall St has extrapolated further increases and projects that annual Free Cash Flow could rise to nearly $235 million by 2035.
Based on these cash flow projections, the DCF model calculates Teladoc Health’s intrinsic value at $15.62 per share. With the current market price trading at a 47.3% discount compared to this estimate, the stock appears noticeably undervalued using this method.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Teladoc Health is undervalued by 47.3%. Track this in your watchlist or portfolio, or discover 848 more undervalued stocks based on cash flows.
Approach 2: Teladoc Health Price vs Sales
The Price-to-Sales (P/S) ratio is often the preferred valuation multiple when evaluating unprofitable or fast-growing companies, as is the case with Teladoc Health. It allows investors to compare a company’s market value to its total sales, offering perspective on how much the market is willing to pay for each dollar of revenue.
Growth expectations and risk play a big role in determining what counts as a “normal” or “fair” P/S ratio. Higher expected revenue growth or industry tailwinds can justify a higher multiple, while heightened risks or slowing growth often drag it lower.
Currently, Teladoc Health trades at a P/S ratio of 0.57x, which is well below the Healthcare Services industry average of 3.50x and its peers’ average of 3.94x. While these benchmarks provide context, they do not capture the company’s unique mix of revenue growth, profitability outlook, market size, and risk profile.
This is where Simply Wall St’s “Fair Ratio” comes in. For Teladoc, the Fair P/S Ratio is calculated at 2.08x. Unlike simple industry or peer comparisons, the Fair Ratio adjusts for factors like earnings growth, risk, profit margins, and the company’s specific characteristics, creating a more accurate picture of true value.
With the current multiple of 0.57x substantially below the Fair Ratio of 2.08x, Teladoc Health looks undervalued on this measure as well.
Result: UNDERVALUED
PS ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1382 companies where insiders are betting big on explosive growth.
Upgrade Your Decision Making: Choose your Teladoc Health Narrative
Earlier we mentioned that there is an even better way to understand valuation, so let's introduce you to Narratives. A Narrative is simply a way for you to capture your perspective on a company by connecting its story and business drivers to your own forecasts for its future revenue, earnings, and margins. You can then see how those assumptions map to a Fair Value.
Narratives are powerful because they link what you believe about Teladoc Health’s growth, risks, and strategy directly to a financial forecast and fair value estimate. This makes your investment decisions much more personal and transparent than simply relying on traditional ratios or analyst targets.
Accessible right on Simply Wall St's Community page, Narratives are easy to use and trusted by millions of investors worldwide. By updating dynamically with each new earnings report or market-moving headline, Narratives help you track whether your fair value moves closer to or further from the current share price, so you can decide when to buy or sell based on your own thesis.
For example, some investors may believe Teladoc Health’s international expansion and innovative digital programs justify the highest analyst target of $12.00 per share. Others may focus on margin pressure and ongoing losses, landing closer to the $7.00 per share bearish estimate. Narratives let you choose the story that fits your view.
Do you think there's more to the story for Teladoc Health? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com